These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31113993)

  • 1. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
    Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
    Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
    Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
    Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
    Slusarczyk M; Lopez MH; Balzarini J; Mason M; Jiang WG; Blagden S; Thompson E; Ghazaly E; McGuigan C
    J Med Chem; 2014 Feb; 57(4):1531-42. PubMed ID: 24471998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine.
    Masoudi M; Seki M; Yazdanparast R; Yachie N; Aburatani H
    Sci Rep; 2019 Dec; 9(1):19188. PubMed ID: 31844142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
    Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
    Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
    Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
    Kuroda H; Tachikawa M; Uchida Y; Inoue K; Ohtsuka H; Ohtsuki S; Unno M; Terasaki T
    Eur J Pharm Sci; 2017 May; 103():116-121. PubMed ID: 28215943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
    Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
    Wu W; Sigmond J; Peters GJ; Borch RF
    J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
    Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells.
    You L; Chang D; Du HZ; Zhao YP
    Biochem Biophys Res Commun; 2011 Apr; 407(1):1-6. PubMed ID: 21316338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUC-1031 in biliary tract cancer: from bench to bedside and back?
    Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
    Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.